APO RESEARCH · REPORT
Infantile Spasms Therapeutics
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Product & engineering
Understand the product.
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Selected research
Market Structure
Global Infantile Spasms Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with stiffening of the arms and legs; some children arch their backs as they extend their arms and legs. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life.
Global Infantile Spasms Therapeutics key players include Mallinckrodt, H. Lundbeck, etc. Global top two manufacturers hold a share over 60%.
In terms of product, Oral is the largest segment, with a share obout 55%. And in terms of application, the largest application is Hospital, followed by Clinic, etc.
Read the full market overview
Report Includes
This report provides an overview of the global Infantile Spasms Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Infantile Spasms Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Infantile Spasms Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Infantile Spasms Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Infantile Spasms Therapeutics Segment by Company
Mallinckrodt
H. Lundbeck
Insys Therapeutics
Orphelia Pharma
Valerion Therapeutics
Catalyst Pharmaceuticals
Anavex Life Sciences
Retrophin
GW Pharmaceuticals
Infantile Spasms Therapeutics Segment by Type
Oral
Injection
Infantile Spasms Therapeutics Segment by Application
Hospital
Clinic
Other
Infantile Spasms Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infantile Spasms Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infantile Spasms Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infantile Spasms Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Infantile Spasms Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infantile Spasms Therapeutics industry.
Chapter 3: Detailed analysis of Infantile Spasms Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Infantile Spasms Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
Applications
- Hospital
- Clinic
- Other
Companies covered
- Mallinckrodt
- H. Lundbeck
- Insys Therapeutics
- Orphelia Pharma
- Valerion Therapeutics
- Catalyst Pharmaceuticals
- Anavex Life Sciences
- Retrophin
- GW Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Infantile Spasms Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Injection
- 1.3 Market Analysis by Application
- 1.3.1 Global Infantile Spasms Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Infantile Spasms Therapeutics Growth Trends by Region
- 1.5.1 Global Infantile Spasms Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Infantile Spasms Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Infantile Spasms Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Infantile Spasms Therapeutics Market Dynamics
- 2.1 Infantile Spasms Therapeutics Industry Trends
- 2.2 Infantile Spasms Therapeutics Industry Drivers
- 2.3 Infantile Spasms Therapeutics Industry Opportunities and Challenges
- 2.4 Infantile Spasms Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Infantile Spasms Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Infantile Spasms Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Infantile Spasms Therapeutics Key Company Head office and Area Served
- 3.4 Global Infantile Spasms Therapeutics Company, Product Type & Application
- 3.5 Global Infantile Spasms Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Infantile Spasms Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Infantile Spasms Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Infantile Spasms Therapeutics Tier 1, Tier 2, and Tier 3
4 Infantile Spasms Therapeutics Market by Type
- 4.1 Global Infantile Spasms Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Infantile Spasms Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Infantile Spasms Therapeutics Market Size Share by Type (2021-2032)
5 Infantile Spasms Therapeutics Market by Application
- 5.1 Global Infantile Spasms Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Infantile Spasms Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Infantile Spasms Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Mallinckrodt
- 6.1.1 Mallinckrodt Company Information
- 6.1.2 Mallinckrodt Business Overview
- 6.1.3 Mallinckrodt Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Mallinckrodt Infantile Spasms Therapeutics Product Portfolio
- 6.1.5 Mallinckrodt Recent Developments
- 6.2 H. Lundbeck
- 6.2.1 H. Lundbeck Company Information
- 6.2.2 H. Lundbeck Business Overview
- 6.2.3 H. Lundbeck Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 H. Lundbeck Infantile Spasms Therapeutics Product Portfolio
- 6.2.5 H. Lundbeck Recent Developments
- 6.3 Insys Therapeutics
- 6.3.1 Insys Therapeutics Company Information
- 6.3.2 Insys Therapeutics Business Overview
- 6.3.3 Insys Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Insys Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 6.3.5 Insys Therapeutics Recent Developments
- 6.4 Orphelia Pharma
- 6.4.1 Orphelia Pharma Company Information
- 6.4.2 Orphelia Pharma Business Overview
- 6.4.3 Orphelia Pharma Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Orphelia Pharma Infantile Spasms Therapeutics Product Portfolio
- 6.4.5 Orphelia Pharma Recent Developments
- 6.5 Valerion Therapeutics
- 6.5.1 Valerion Therapeutics Company Information
- 6.5.2 Valerion Therapeutics Business Overview
- 6.5.3 Valerion Therapeutics Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Valerion Therapeutics Infantile Spasms Therapeutics Product Portfolio
- 6.5.5 Valerion Therapeutics Recent Developments
- 6.6 Catalyst Pharmaceuticals
- 6.6.1 Catalyst Pharmaceuticals Company Information
- 6.6.2 Catalyst Pharmaceuticals Business Overview
- 6.6.3 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Catalyst Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 6.6.5 Catalyst Pharmaceuticals Recent Developments
- 6.7 Anavex Life Sciences
- 6.7.1 Anavex Life Sciences Company Information
- 6.7.2 Anavex Life Sciences Business Overview
- 6.7.3 Anavex Life Sciences Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Anavex Life Sciences Infantile Spasms Therapeutics Product Portfolio
- 6.7.5 Anavex Life Sciences Recent Developments
- 6.8 Retrophin
- 6.8.1 Retrophin Company Information
- 6.8.2 Retrophin Business Overview
- 6.8.3 Retrophin Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Retrophin Infantile Spasms Therapeutics Product Portfolio
- 6.8.5 Retrophin Recent Developments
- 6.9 GW Pharmaceuticals
- 6.9.1 GW Pharmaceuticals Company Information
- 6.9.2 GW Pharmaceuticals Business Overview
- 6.9.3 GW Pharmaceuticals Infantile Spasms Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 GW Pharmaceuticals Infantile Spasms Therapeutics Product Portfolio
- 6.9.5 GW Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Infantile Spasms Therapeutics Market Size (2021-2032)
- 7.2 North America Infantile Spasms Therapeutics Market Size by Type
- 7.2.1 North America Infantile Spasms Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Infantile Spasms Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Infantile Spasms Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Infantile Spasms Therapeutics Market Size by Application
- 7.3.1 North America Infantile Spasms Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Infantile Spasms Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Infantile Spasms Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Infantile Spasms Therapeutics Market Size by Country
- 7.4.1 North America Infantile Spasms Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Infantile Spasms Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Infantile Spasms Therapeutics Market Size (2021-2032)
- 8.2 Europe Infantile Spasms Therapeutics Market Size by Type
- 8.2.1 Europe Infantile Spasms Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Infantile Spasms Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Infantile Spasms Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Infantile Spasms Therapeutics Market Size by Application
- 8.3.1 Europe Infantile Spasms Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Infantile Spasms Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Infantile Spasms Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Infantile Spasms Therapeutics Market Size by Country
- 8.4.1 Europe Infantile Spasms Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Infantile Spasms Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Infantile Spasms Therapeutics Market Size (2021-2032)
- 9.2 China Infantile Spasms Therapeutics Market Size by Type
- 9.2.1 China Infantile Spasms Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Infantile Spasms Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Infantile Spasms Therapeutics Market Share by Type (2021-2032)
- 9.3 China Infantile Spasms Therapeutics Market Size by Application
- 9.3.1 China Infantile Spasms Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Infantile Spasms Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Infantile Spasms Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Infantile Spasms Therapeutics Market Size (2021-2032)
- 10.2 Asia Infantile Spasms Therapeutics Market Size by Type
- 10.2.1 Asia Infantile Spasms Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Infantile Spasms Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Infantile Spasms Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Infantile Spasms Therapeutics Market Size by Application
- 10.3.1 Asia Infantile Spasms Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Infantile Spasms Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Infantile Spasms Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Infantile Spasms Therapeutics Market Size by Country
- 10.4.1 Asia Infantile Spasms Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Infantile Spasms Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Infantile Spasms Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Infantile Spasms Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Infantile Spasms Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Infantile Spasms Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst